Anthos Therapeutics launched in 2019 thanks to private equity investments with the express goal of creating new therapies for patients suffering from high-risk cardiovascular issues. Anthos recently announced that they had developed a new drug that could significantly reduce the risk of blood clots, providing a safer alternative for the 12.1 million Americans expected to suffer from atrial fibrillation by 2030.